GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biophytis SA (OTCPK:BPTSY) » Definitions » Capital Expenditure

Biophytis (Biophytis) Capital Expenditure : $-0.24 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Biophytis Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Biophytis's cash flow for capital expenditures for the six months ended in Dec. 2023 was $-0.14 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.24 Mil.

Biophytis Capital Expenditure Historical Data

The historical data trend for Biophytis's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biophytis Capital Expenditure Chart

Biophytis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.31 -0.26 -0.39 -0.15 -0.24

Biophytis Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.36 -0.02 -0.13 -0.10 -0.14

Biophytis Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biophytis (Biophytis) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biophytis SA (OTCPK:BPTSY) » Definitions » Capital Expenditure
Comparable Companies
XPAR:ALVET XPAR:ALMDP XPAR:ALQGC XPAR:ALTME XPAR:ALINT XPAR:ALPAT XPAR:ALTHX XPAR:ALNFL XPAR:ALNEV XPAR:ALPHA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
ALBPS:France 6XB:Germany
Address
BC 9, Batiment A 4eme etage, 4 pace Jussieu, Sorbonne University, Paris, FRA, 75005
Website
https://www.biophytis.com
Biophytis SA is a France-based biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Its drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD.